Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 17/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476359 | 0.92 | GNRHR (0.58) | GNRHR | |
| SCHEMBL6476190 | 0.89 | GNRHR (0.62) | GNRHRTSHRSMN1; SMN2 | |
| SCHEMBL6476478 | 0.88 | GNRHR (0.65) | GNRHRTSHR | |
| SCHEMBL6487480 | 0.87 | GNRHR (0.53) | GNRHR | |
| SCHEMBL6484994 | 0.87 | GNRHR (0.51) | GNRHRMAPTSMN1; SMN2 | |
| SCHEMBL6477028 | 0.85 | GNRHR (0.73) | GNRHR | |
| SCHEMBL6485607 | 0.85 | GNRHR (0.73) | GNRHRKDM4EMAPTTSHRSMN1; SMN2 | |
| SCHEMBL6485685 | 0.83 | GNRHR (0.55) | GNRHR | |
| SCHEMBL6488879 | 0.82 | GNRHR (0.62) | GNRHR | |
| SCHEMBL6476059 | 0.82 | GNRHR (0.64) | GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951858-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050075339-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-6673796-B2 | SEXUAL DISORDERS | NEUROCRINE BIOSCIENCES, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030114455-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114455-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885KDM4E 2382/4885MAPT 4751/4885 |
| US-20050075339-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, LHCGR, GHRHR | GNRHR 1/4885KDM4E 2406/4885MAPT 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.